Menu Search
Equities

Kiora Pharmaceuticals Inc

KPRX:NAQ

Kiora Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.31
  • Today's Change-0.11 / -3.22%
  • Shares traded3.20k
  • 1 Year change-34.33%
  • Beta-0.4414
Data delayed at least 15 minutes, as of Nov 21 2024 20:43 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Kiora Pharmaceuticals Inc have a median target of 27.00, with a high estimate of 54.00 and a low estimate of 10.00. The median estimate represents a 715.71% increase from the last price of 3.31.
High1,531.4%54.00
Med715.7%27.00
Low202.1%10.00

Earnings history & estimates in USD

On Nov 08, 2024, Kiora Pharmaceuticals Inc reported 3rd quarter 2024 losses of -0.81 per share.
The next earnings announcement is expected on Mar 26, 2025.
Average growth rate-2.82%
Kiora Pharmaceuticals Inc reported annual 2023 losses of -24.21 per share on Mar 25, 2024.
Average growth rate+44.98%
More ▼

Revenue history & estimates in USD

EyeGate Pharmaceuticals, Inc. did not report revenues for the 3rd quarter 2024. However, during the 3rd quarter of the prior year the company reported revenues of 0.00.
Average growth rate-66.63%
EyeGate Pharmaceuticals, Inc. did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate-49.89%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.